Real Estate Investment Trust (Healthcare/Medical Facilities)
Strategic Profile
2025 was a transformational year, with a revamped asset management platform, US$1.20 billion of asset sales exiting 14 non-core markets, improved leasing performance, and the launch of a US$600 million commercial paper program. The company set a $1.61 FFO midpoint for 2026 and is strengthening the balance sheet while targeting NOI growth. The portfolio streamlining and operational improvements target improved cash flow stability and profitability.
Cyborg Score Rationale
Healthcare Realty Trust is underperforming both the healthcare REIT sector and REITs overall, with volatile FFO, a recent dividend cut, and an ongoing strategic overhaul. However, the company set FY 2026 guidance at 1.580-1.640 EPS, significantly above analyst expectations. Management has demonstrated commitment to balance sheet strengthening and operational execution.
Top Insights
2026 EPS guidance of 1.580-1.640 significantly exceeded prior consensus estimate of 0.590
Annual dividend yield of 6.29%, higher than both US industry average of 4.98% and market average of 3.77%
2025 revenue declined 6.93% to $1.18 billion year-over-year
Analyst consensus rating is "Hold" with average price target of $19.13
Named Competitors
National Health Investors — Senior housing and medical facility REIT
Global Medical REIT — Healthcare facility real estate operator
Sabra Health Care REIT — Senior housing and healthcare properties
Recent Developments
(Feb 2026) Announced $600 million commercial paper program to enhance short-term liquidity and funding flexibility